Europe Collaborates on Generic Drugs

News
Article

The European Medicines Agency plans on sharing generic-drug assessment reports with regulators outside the European Union.

 

As part of the International Generic Drug Regulators Pilot (IGDRP), the European Medicines Agency (EMA) is providing the agency’s assessments of applications for generic medicines in real time with collaborating regulatory agencies outside the European Union (EU). EMA is sharing the assessments as part of an information-sharing initiative to ensure timely authorization and availability of generic drugs.

IGDRP was started in July 2014 using the EU-decentralized procedure as a model, and it is now extended to the centralized procedure.  According to the EMA, the aim of the pilot is to “both save global assessment resources and to facilitate and strengthen the scientific assessment process for medicines. It is expected that this sharing of assessments will allow authorization of generic products in concerned countries in a coordinated and resource effective way.”

Source: European Medicines Agency

Recent Videos
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments